Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.00 GBP
−2.48 M GBP
0.00 GBP
452.43 M
About ImmuPharma plc
Sector
Industry
CEO
Timothy Paul McCarthy
Website
Headquarters
London
Founded
2000
ISIN
GB0033711010
FIGI
BBG000C01SG5
ImmuPharma Plc engages in the research, development, and commercialization of pharmaceutical products. It is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The firm's portfolio consists of four novel peptide therapy areas: autoimmunity, metabolism, cancer and anti-infectives. Its drug Lupuzor, is a potential treatment for the autoimmune chronic inflammatory disease lupus. The company was founded by Richard Warr and Dimitri F. Dimitriou in 1999 and is headquartered in London, the United Kingdom.
Related stocks
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of IMM is 11.90 GBX — it has decreased by −5.18% in the past 24 hours. Watch ImmuPharma plc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange ImmuPharma plc stocks are traded under the ticker IMM.
IMM stock has risen by 13.33% compared to the previous week, the month change is a 161.54% rise, over the last year ImmuPharma plc has showed a 516.90% increase.
IMM stock is 15.88% volatile and has beta coefficient of 1.02. Track ImmuPharma plc stock price on the chart and check out the list of the most volatile stocks — is ImmuPharma plc there?
Today ImmuPharma plc has the market capitalization of 59.82 M, it has increased by 1.80% over the last week.
Yes, you can track ImmuPharma plc financials in yearly and quarterly reports right on TradingView.
ImmuPharma plc is going to release the next earnings report on May 26, 2026. Keep track of upcoming events with our Earnings Calendar.
IMM net income for the last half-year is −1.84 M GBP, while the previous report showed −2.10 M GBP of net income which accounts for 12.25% change. Track more ImmuPharma plc financial stats to get the full picture.
No, IMM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, IMM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ImmuPharma plc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ImmuPharma plc technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ImmuPharma plc stock shows the buy signal. See more of ImmuPharma plc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.